Cargando…

Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?

PURPOSE: Radiation therapy (RT) improves control of Hodgkin lymphoma (HL), but patients who undergo RT are at risk for late effects, including cardiovascular disease and second cancers, because of radiation doses to organs at risk (OARs). Proton therapy (PT) can reduce OAR doses compared with conven...

Descripción completa

Detalles Bibliográficos
Autores principales: Ntentas, Georgios, Dedeckova, Katerina, Andrlik, Michal, Aznar, Marianne C., George, Ben, Kubeš, Jiří, Darby, Sarah C., Cutter, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493042/
https://www.ncbi.nlm.nih.gov/pubmed/30708133
http://dx.doi.org/10.1016/j.prro.2019.01.006
_version_ 1783415173958074368
author Ntentas, Georgios
Dedeckova, Katerina
Andrlik, Michal
Aznar, Marianne C.
George, Ben
Kubeš, Jiří
Darby, Sarah C.
Cutter, David J.
author_facet Ntentas, Georgios
Dedeckova, Katerina
Andrlik, Michal
Aznar, Marianne C.
George, Ben
Kubeš, Jiří
Darby, Sarah C.
Cutter, David J.
author_sort Ntentas, Georgios
collection PubMed
description PURPOSE: Radiation therapy (RT) improves control of Hodgkin lymphoma (HL), but patients who undergo RT are at risk for late effects, including cardiovascular disease and second cancers, because of radiation doses to organs at risk (OARs). Proton therapy (PT) can reduce OAR doses compared with conventional photon RT. However, access to PT is currently limited, so referrals must be appropriately selective. We aimed to identify subgroups of patients with HL who could benefit the most dosimetrically from RT with PT based on the prechemotherapy disease characteristics. METHODS AND MATERIALS: Normal tissue radiation doses were calculated for 21 patients with HL who were treated with deep-inspiration breath-hold pencil-beam scanning (PBS) PT and compared with doses from 3-dimensional conformal (3D-CRT) and partial arc volumetric modulated (PartArc) photon RT. Prechemotherapy disease characteristics associated with significant dosimetric benefits from PBS compared with photon RT were identified. RESULTS: Treatment with PBS was well tolerated and provided with good local control. PBS provided dosimetric advantages for patients whose clinical treatment volume extended below the seventh thoracic level and for female patients with axillary disease. In addition, an increasing dosimetric benefit for some OARs was observed for increasing target volume. PBS significantly reduced the mean dose to the heart, breast, lungs, spinal cord, and esophagus. Dose homogeneity and conformity within the target volume were also superior with PBS, but some high-dose measures and hot spots were increased with PBS compared with partial arc volumetric modulated photon RT. CONCLUSIONS: PBS gives good target coverage and local control while providing reductions in radiation dose to OARs for individuals who receive RT for HL compared with advanced photon RT. Our findings highlight groups of patients who would be expected to gain more dosimetric benefit from PBS. These findings facilitate the selection of patients who should be considered a priority for PT.
format Online
Article
Text
id pubmed-6493042
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-64930422019-05-07 Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? Ntentas, Georgios Dedeckova, Katerina Andrlik, Michal Aznar, Marianne C. George, Ben Kubeš, Jiří Darby, Sarah C. Cutter, David J. Pract Radiat Oncol Article PURPOSE: Radiation therapy (RT) improves control of Hodgkin lymphoma (HL), but patients who undergo RT are at risk for late effects, including cardiovascular disease and second cancers, because of radiation doses to organs at risk (OARs). Proton therapy (PT) can reduce OAR doses compared with conventional photon RT. However, access to PT is currently limited, so referrals must be appropriately selective. We aimed to identify subgroups of patients with HL who could benefit the most dosimetrically from RT with PT based on the prechemotherapy disease characteristics. METHODS AND MATERIALS: Normal tissue radiation doses were calculated for 21 patients with HL who were treated with deep-inspiration breath-hold pencil-beam scanning (PBS) PT and compared with doses from 3-dimensional conformal (3D-CRT) and partial arc volumetric modulated (PartArc) photon RT. Prechemotherapy disease characteristics associated with significant dosimetric benefits from PBS compared with photon RT were identified. RESULTS: Treatment with PBS was well tolerated and provided with good local control. PBS provided dosimetric advantages for patients whose clinical treatment volume extended below the seventh thoracic level and for female patients with axillary disease. In addition, an increasing dosimetric benefit for some OARs was observed for increasing target volume. PBS significantly reduced the mean dose to the heart, breast, lungs, spinal cord, and esophagus. Dose homogeneity and conformity within the target volume were also superior with PBS, but some high-dose measures and hot spots were increased with PBS compared with partial arc volumetric modulated photon RT. CONCLUSIONS: PBS gives good target coverage and local control while providing reductions in radiation dose to OARs for individuals who receive RT for HL compared with advanced photon RT. Our findings highlight groups of patients who would be expected to gain more dosimetric benefit from PBS. These findings facilitate the selection of patients who should be considered a priority for PT. Elsevier 2019-05 /pmc/articles/PMC6493042/ /pubmed/30708133 http://dx.doi.org/10.1016/j.prro.2019.01.006 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ntentas, Georgios
Dedeckova, Katerina
Andrlik, Michal
Aznar, Marianne C.
George, Ben
Kubeš, Jiří
Darby, Sarah C.
Cutter, David J.
Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
title Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
title_full Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
title_fullStr Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
title_full_unstemmed Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
title_short Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
title_sort clinical intensity modulated proton therapy for hodgkin lymphoma: which patients benefit the most?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493042/
https://www.ncbi.nlm.nih.gov/pubmed/30708133
http://dx.doi.org/10.1016/j.prro.2019.01.006
work_keys_str_mv AT ntentasgeorgios clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost
AT dedeckovakaterina clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost
AT andrlikmichal clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost
AT aznarmariannec clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost
AT georgeben clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost
AT kubesjiri clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost
AT darbysarahc clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost
AT cutterdavidj clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost